Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (5867)	10/8/1998 4:42:00 PM
From: John F. Dowd	Read Replies (1) \| Respond to of 9523

Biaxin, which is facing increased competition from Pfizer Inc.'s Zithromax: Yes there is a big advantage of the PFE product over Biaxin. 1. Most people who take Biaxin feel that the cure is worse than the sickness. 2 With ZMax the number of doses is considerably less therefore patients have less chance of not taking the entire round of anti-biotics. Most folks don't take their antibiotics for the entire prescribed dosage and super bugs emerge. I agree Pfizer is definitely not a one pony stable. John